Anti-Infectives
Infectious disease is an area of great unmet medical need. Pfizer is a global leader in anti-infective research and development.
Cardiovascular and Metabolic Diseases
The current projections for growth in the prevalence of diabetes threaten to create a global public health crisis. WHO predicts that the worldwide prevalence of diabetes will grow from 171 million in 2000 to 373 million by 2030.
Immunology and Autoimmunity
Pfizer is a global leader in developing medicines for patients suffering from chronic inflammatory and immune diseases.
Inflammation and Remodeling
The Inflammation and Remodeling research unit's goal is to discover and develop novel and differentiated therapeutic options targeting chronic inflammatory diseases.
Neuroscience
In the US today, 7 of the 10 leading causes of disability are neurological and psychiatric disorders. To meet these patient needs, Pfizer is taking a bold leadership approach that will evolve from dealing with symptoms to modifying diseases, where scientifically feasible.
Oncology
Pfizer's Oncology Research Unit (ORU) strives to advance the frontiers of cancer biology and to translate this knowledge into high-impact medicines for cancer patients. The ORU comprises four pillars: Tumor Cell Biology; Bioconjugates Discovery and Development; Precision Medicine; and Integrative Biology and Biochemistry.
Ophthalmology
Pfizer is committed to developing novel therapies that improve the lives of patients with ophthalmic diseases. Our in-line medicines in this area include Xalatan® (latanoprost ophthalmic solution), Xalacom® (latanoprost and timolol), and Macugen® (pegaptanib injection).
Orphan and Genetic Diseases
The mission of the Pfizer Orphan and Genetic Disease Research Unit (OGD) is to create next generation medicines through exploring pathogenic mechanisms that apply to clusters of monogenic diseases.
Pain and Sensory Disorders
Pfizer is a global leader in pain medicines with products in each of the major classes: Celebrex® (celecoxib; COX2 inhibitor), Lyrica® (pregabalin) and Neurontin® (gabapentin; a2d ligands), Avinza® (morphine sulphate; opioid agonist).
Vaccines
Our vision is to become a recognized leader in the development of prophylactic and therapeutic vaccines for all stages of life and for all geographies.
Biotherapeutics Discovery
Pfizer strives to become the leading biotherapeutics company by building on internal expertise and fostering strategic partnerships to access the best technologies with patent protection and technical capabilities that provide a competitive advantage.
Small Molecule Therapeutics Discovery
Pfizer's Worldwide Medicinal Chemistry core capabilities are small molecule design and associated functions including structural biology and computational chemistry, synthetic innovation and compound safety prediction.
Biologics Production and Process Development
WRD Pharmaceutical Sciences envisions a network of strategic partnerships integral to its biologics technology initiatives, which include monoclonal antibody development and manufacturing and prokaryotic expression to augment core competencies.
Small Molecule Production and Process Development
WRD Pharmaceutical Sciences envisions a network of partners to enhance active pharmaceutical ingredients (API) and drug product development and manufacturing of small molecules.
Precision/Personalized Medicine
Precision/Personalized Medicine is an approach to discovering and developing medicines and vaccines that deliver superior outcomes for patients, by integrating clinical and molecular information to understand the biological basis of disease.
Drug Safety
Pfizer's Drug Safety R&D group develops and applies the skills, experience and scientific tools necessary for safety assessment and risk management of targets and compounds across the research, development and commercial phases of drug development.
Pharmacokinetics, Dynamics and Metabolism (PDM)
PDM is focused on the development of innovative small molecule and biotherapeutics therapies through improved understanding of targets, pathways and modeling for preclinical efficacy, discrete toxicity, and safety biomarkers.
